Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.

SLDB has been the topic of a number of research analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. Guggenheim initiated coverage on shares of Solid Biosciences in a research note on Friday. They issued a “buy” rating and a $26.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a report on Friday. Finally, Wedbush reissued an “outperform” rating and set a $14.00 target price on shares of Solid Biosciences in a research note on Wednesday, March 11th.

Insider Activity at Solid Biosciences

In other news, CFO Kevin Tan sold 5,404 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total transaction of $31,451.28. Following the sale, the chief financial officer directly owned 99,422 shares of the company’s stock, valued at $578,636.04. The trade was a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ilan Ganot sold 7,205 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total value of $46,400.20. Following the sale, the director directly owned 25,271 shares in the company, valued at $162,745.24. This trade represents a 22.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 597,672 shares of company stock worth $3,816,546. 13.63% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Solid Biosciences

A number of institutional investors have recently bought and sold shares of SLDB. AQR Capital Management LLC purchased a new stake in Solid Biosciences during the first quarter valued at about $418,000. Goldman Sachs Group Inc. increased its position in shares of Solid Biosciences by 32.2% in the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock worth $667,000 after acquiring an additional 43,910 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of Solid Biosciences during the first quarter valued at approximately $2,338,000. ProShare Advisors LLC acquired a new stake in shares of Solid Biosciences during the second quarter valued at approximately $80,000. Finally, Geode Capital Management LLC lifted its position in shares of Solid Biosciences by 184.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock valued at $7,356,000 after acquiring an additional 979,294 shares in the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Solid Biosciences Stock Performance

Shares of NASDAQ SLDB opened at $7.03 on Monday. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $8.72. The firm has a market cap of $547.71 million, a P/E ratio of -3.48 and a beta of 2.64. The stock has a fifty day moving average price of $6.43 and a two-hundred day moving average price of $5.80.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. On average, research analysts predict that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.